Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Harvard Business School
QuintilesIMS
Colorcon
McKesson
Fish and Richardson
Cerilliant
US Department of Justice
Cipla

Generated: April 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,488,960

« Back to Dashboard

Which drugs does patent 6,488,960 protect, and when does it expire?

Patent 6,488,960 protects RAYOS and is included in one NDA.

This patent has fifteen patent family members in seven countries.
Summary for Patent: 6,488,960
Title: Corticosteroid formulation
Abstract:The present invention pertains to a unit dose formulation comprising 0.25 to 2 mg of a corticosteroid. This small dose can be used to treat rheumatoid arthritis, especially if adapted to release at least 90% by weight of the corticosteroid, 2 to 8 hours after administration.
Inventor(s): Bardsley; Hazel Judith (Cambridge, GB)
Assignee: Arakis Ltd. (GB)
Application Number:09/936,586
Patent Claim Types:
see list of patent claims
Formulation; Compound; Use;

Drugs Protected by US Patent 6,488,960

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Horizon Pharma RAYOS prednisone TABLET, DELAYED RELEASE;ORAL 202020-001 Jul 26, 2012 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y TREATMENT OF RHEUMATOID ARTHRITIS BY DELAYED RELEASE FORMULATION OF 1MG OR 2MG OF PREDNISONE ➤ Try a Free Trial
Horizon Pharma RAYOS prednisone TABLET, DELAYED RELEASE;ORAL 202020-002 Jul 26, 2012 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y TREATMENT OF RHEUMATOID ARTHRITIS BY DELAYED RELEASE FORMULATION OF 1MG OR 2MG OF PREDNISONE ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,488,960

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9905898Mar 15, 1999
PCT Information
PCT FiledMarch 14, 2000PCT Application Number:PCT/GB00/00924
PCT Publication Date:September 21, 2000PCT Publication Number: WO00/54780

Non-Orange Book US Patents Family Members for Patent 6,488,960

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,677,326 Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,488,960

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 1158988 ➤ Try a Free Trial
European Patent Office 1318816 ➤ Try a Free Trial
United Kingdom 0023220 ➤ Try a Free Trial
United Kingdom 9905898 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Harvard Business School
Express Scripts
McKinsey
Boehringer Ingelheim
Colorcon
Farmers Insurance
Covington
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.